Azithromycin distinctively modulates classical activation of human monocytes in vitro

British Journal of Pharmacology

Volumn 165, Issue 5, 2012, Pages 1348-1360

  Vrancic M ^a   Banjanac, M ^a   Nujic K ^a   Bosnar, M ^a   Murati, T ^a   Munic V ^a   Stupin Polancec D ^a   Belamaric D ^a   Parnham, M J ^a   Erakovic Haber V ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

anti inflammatory drug; azithromycin; classical activation; dexamethasone; human macrophage; human monocyte; lysosome affecting agent; roflumilast; SB203580; TLR4 signalling

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AMMONIUM CHLORIDE; AZITHROMYCIN; CCL18 CHEMOKINE; CD163 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CCR7; CHLOROQUINE; CONCANAMYCIN A; CXCL11 CHEMOKINE; DEXAMETHASONE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 6; MACROPHAGE DERIVED CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; ROFLUMILAST; STAT1 PROTEIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CCL18 GENE; CCL2 GENE; CCL22 GENE; CCL5 GENE; CCR7 GENE; CD163 GENE; CD206 GENE; CELL ACTIVATION; CONTROLLED STUDY; CXCL11 GENE; CYTOKINE RELEASE; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; GAPDH GENE; GENE EXPRESSION; GENE PRODUCT; HUMAN; HUMAN CELL; IL10 GENE; IN VITRO STUDY; LYSOSOME; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; AZITHROMYCIN; CELLS, CULTURED; CHEMOKINE CCL2; CHEMOKINE CCL22; CHEMOKINES, CC; DOWN-REGULATION; GENE EXPRESSION; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LYSOSOMES; MACROPHAGE ACTIVATION; MACROPHAGES; MONOCYTES; NF-KAPPA B; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84857078932     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01576.x     Document Type: Article

References (40)

1. Basque J, Martel M, Leduc R, Cantin AM, (2008). Lysosomotropic drugs inhibit maturation of transforming growth factor-beta. Can J Physiol Pharmacol 86: 606-612.
2. Benachour N, Seralini GE, (2009). Glyphosate formulations induce apoptosis and necrosis in human umbilical, embryonic, and placental cells. Chem Res Toxicol 22: 97-105.
3. Benoit M, Desnues B, Mege JL, (2008). Macrophage polarization in bacterial infections. J Immunol 181: 3733-3739.
4. Bosnar M, Bošnjak B, Čužić S, Hrvačić B, Marjanović N, Glojnarić I, et al,. (2009). Azithromycin and clarithromycin inhibit lipopolysaccharide-induced murine pulmonary neutrophilia mainly through effects on macrophage-derived granulocyte-macrophage colony stimulating factor and interleukin-1β. J Pharm Exp Ther 331: 104-113.
5. Brikos C, O'Neill LA, (2008). Signalling of toll-like receptors. Handb Exp Pharmacol 183: 21-50.
6. Carlier MB, Garcia-Luque I, Montenez JP, Tulkens PM, Piret J, (1994). Accumulation, release and subcellular localization of azithromycin in phagocytic and non-phagocytic cells in culture. Int J Tissue React 16: 211-220.
7. Carpenter S, O'Neill LA, (2009). Recent insights into the structure of Toll-like receptors and post-translational modifications of their associated signalling proteins. Biochem J 422: 1-10.
8. Crosbie PA, Woodhead MA, (2009). Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 33: 171-181.
9. Čulić O, Eraković V, Parnham MJ, (2001). Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 429: 209-229.
10. Darieva Z, Lasunskaia EB, Campos MN, Kipnis TL, Da Silva WD, (2004). Activation of phosphatidylinositol 3-kinase and c-Jun-N-terminal kinase cascades enhances NF-kappaB-dependent gene transcription in BCG-stimulated macrophages through promotion of p65/p300 binding. J Leukoc Biol 75: 689-697.
11. Eswarappa SM, Basu N, Joy O, Chakravortty D, (2008). Folimycin (concanamycin A) inhibits LPS-induced nitric oxide production and reduces surface localization of TLR4 in murine macrophages. Innate Immun 14: 13-24.
12. Fox RI, (1993). Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 23 (Suppl 1): 82-91.
13. Gordon S, Martinez FO, (2010). Alternative activation of macrophages: mechanism and functions. Immunity 32: 593-604.
14. Gordon S, Taylor PR, (2005). Monocyte and macrophage heterogeneity. Nat Rev Immunol 5: 953-964.
15. Gotfried MH, (2004). Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 125: 52S-61S.
16. Heinrich A, Balszuweit F, Thiermann H, Kehe K, (2009). Rapid simultaneous determination of apoptosis, necrosis, and viability in sulfur mustard exposed HaCaT cell cultures. Toxicol Lett 191: 260-267.
17. Hodge S, Hodge G, Jersmann H, Matthews G, Ahern J, Holmes M, et al,. (2008). Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 178: 139-148.
18. Jeong JY, Jue DM, (1997). Chloroquine inhibits processing of tumor necrosis factor in lipopolysaccharide-stimulated RAW 264.7 macrophages. J Immunol 158: 4901-4907.
19. Kanoh S, Rubin BK, (2010). Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 23: 590-615.
20. Levy JA, (2009). The unexpected pleiotropic activities of RANTES. J Immunol 182: 3945-3946.
21. Munić V, Banjanac M, Koštrun S, Nujić K, Bosnar M, Marjanović N, et al,. (2011). Intensity of macrolide anti-inflammatory activity in J774A.1 cells positively correlates with cellular accumulation and phospholipidosis. Pharmacol Res 64: 298-307.
22. Murphy BS, Sundareshan V, Cory TJ, Hayes D Jr, Anstead MI, Feola DJ, (2008). Azithromycin alters macrophage phenotype. J Antimicrob Chemother 61: 554-560.
23. Navarro-Xavier RA, Newson J, Silveira VL, Farrow SN, Gilroy DW, Bystrom J, (2010). A new strategy for the identification of novel molecules with targeted proresolution of inflammation properties. J Immunol 184: 1516-1525.
24. Ostuni R, Zanoni I, Granucci F, (2010). Deciphering the complexity of toll-like receptor signaling. Cell Mol Life Sci 67: 4109-4134.
25. Prêle CM, Woodward EA, Bisley J, Keith-Magee A, Nicholson SE, Hart PH, (2008). SOCS1 regulates the IFN but not NFkappaB pathway in TLR-stimulated human monocytes and macrophages. J Immunol 181: 8018-8026.
26. Qin H, Wilson CA, Lee SJ, Zhao X, Benveniste EN, (2005). LPS induces CD40 gene expression through the activation of NF-kappaB and STAT-1alpha in macrophages and microglia. Blood 106: 3114-3122.
27. Saraiva M, O'Garra A, (2010). The regulation of IL-10 production by immune cells. Nat Rev Immunol 10: 170-181.
28. Shinkai M, Henke MO, Rubin BK, (2008). Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther 117: 393-405.
29. Sobota JA, Bäck N, Eipper BA, Mains RE, (2009). Inhibitors of the V0 subunit of the vacuolar H+-ATPase prevent segregation of lysosomal- and secretory-pathway proteins. J Cell Sci 122: 3542-3553.
30. Sugiyama K, Shirai R, Mukae H, Ishimoto H, Nagata T, Sakamoto N, et al,. (2007). Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells. Clin Exp Immunol 147: 540-546.
31. Swantek JL, Cobb MH, Geppert TD, (1997). Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK. Mol Cell Biol 17: 6274-6282.
32. Tyteca D, Van Der Smissen P, Mettlen M, Van Bambeke F, Tulkens PM, Mingeot-Leclercq MP, et al,. (2002). Azithromycin, a lysosomotropic antibiotic, has distinct effects on fluid-phase and receptor-mediated endocytosis, but does not impair phagocytosis in J774 macrophages. Exp Cell Res 281: 86-100.
33. Tyteca D, Schanck A, Dufrêne YF, Deleu M, Courtoy PJ, Tulkens PM, et al,. (2003). The macrolide antibiotic azithromycin interacts with lipids and affects membrane organization and fluidity: studies on Langmuir-Blodgett monolayers, liposomes and J774 macrophages. J Membr Biol 192: 203-215.
34. Ueno H, Klechevsky E, Morita R, Aspord C, Cao T, Matsui T, et al,. (2007). Dendritic cell subsets in health and disease. Immunol Rev 219: 118-142.
35. Van Bambeke F, Montenez JP, Piret J, Tulkens PM, Courtoy PJ, Mingeot-Leclercq MP, (1996). Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity. Eur J Pharmacol 314: 203-214.
36. Van Gorp H, Delputte PL, Nauwynck HJ, (2010). Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol 47: 1650-1660.
37. Van Lieshout AW, Van der Voort R, le Blanc LM, Roelofs MF, Schreurs BW, van Riel PL, et al,. (2006). Novel insights in the regulation of CCL18 secretion by monocytes and dendritic cells via cytokines, toll-like receptors and rheumatoid synovial fluid. BMC Immunol 7: 23-35.
38. Weber SM, Levitz SM, (2001). Chloroquine antagonizes the proinflammatory cytokine response to opportunistic fungi by alkalizing the fungal phagolysosome. J Infect Dis 183: 935-942.
39. Yamashita U, Kuroda E, (2002). Regulation of macrophage-derived chemokine (MDC, CCL22) production. Crit Rev Immunol 22: 105-114.
40. Yamauchi K, Shibata Y, Kimura T, Abe S, Inoue S, Osaka D, et al,. (2009). Azithromycin suppresses interleukin-12p40 expression in lipopolysaccharide and interferon-gamma stimulated macrophages. Int J Biol Sci 5: 667-678.